Vascular endothelial growth factor at high plasma levels is associated with extranodal involvement in adult T cell leukemia patients
TO THE EDITOR Vascular endothelial growth factor (VEGF) has an important role in tumor biology and in the process of tumour angiogenesis.
1 However, the biological and clinical significance of VEGF in adult T cell leukemia (ATL) is unknown. To address this, we measured the plasma level of VEGF in 60 patients with ATL (acute type, 41 patients; lymphoma type, one patient; chronic type, 16 patients; smouldering type, two patients) and in 26 healthy controls.
The VEGF levels in 26 healthy controls ranged from 8.2 to 42.4 pg/ml (mean ± 2 s.d. = 24.7 ± 19.6), thus we set 44.3 pg/ml for the normal upper limit in this series. As shown in Figure 1 , the VEGF levels at diagnosis were elevated above the normal upper limit in more than half the patients with acute type (7.0-253.1, median 62.8), lymphoma type (60.1), and chronic type (2.0-99.1, median 60.1). However, the levels were normal in smouldering type (14.0, 14.0, median 14.0), indicating that the expression of VEGF is involved in the advanced stage of ATL leukemogenesis.
Salven et al 2 recently demonstrated that a high pretreatment serum VEGF level was associated with poor outcome in non-Hodgkin's lymphoma. For this reason, we examined the prognostic significance of the VEGF level in ATL patients. However, no correlation was observed between VEGF level and survival time as well as ATL cell count, serum LDH level, Ki-67 expression, and the deletions of p15 and/or p16 genes, which were known as prognostic factors (data not shown).
From the examination of the relationship between VEGF and several
Figure 1
VEGF levels in 41 patients with acute ATL, in one patient with lymphoma ATL, in 16 patients with chronic ATL and two patients with smouldering ATL. A plasma sample of heparinized peripheral blood was taken from each patient at diagnosis before chemotherapy and stored at −80°C. VEGF in the plasma was determined using an immunoassay kit for human VEGF (Quantikine VEGF Immunoassay, R&D Systems, Minneapolis, MN, USA) according to the manual. Horizontal dashed line, the mean value +2 s.d. of the VEGF titer in the healthy control group (44.3 pg/ml). clinical features in ATL patients, an interesting correlation between the VEGF level and the presence of extranodal involvement was observed (Table 1) . It was noteworthy that the incidence of extranodal involvement was increased with VEGF level in acute type patients. To support this, we divided these patients as shown in Table 1 , then statistically analyzed the incidence of extranodal involvement in each group. We first analyzed the incidence of the skin lesion, because it has been the most prevalent extranodal involvement in ATL patients. The incidence of the skin lesion in the high VEGF group (у70 pg/ml) and in Table 1 VEGF and extranodal involvement in acute ATL patients
Skin lesion Others CNS, central nervous system. The space divides these acute ATL patients into two groups with a high level of VEGF (у70 pg/ml) and a relatively low level of VEGF (Ͻ70 pg/ml). the low VEGF group (Ͻ70 pg/ml) were 11/19 (57.9%) and 3/22 (13.6%), respectively. This difference was statistically significant (P Ͻ 0.01, Fisher's exact probability method). We further analyzed the incidence of all extranodal involvement, including bone involvement, ascites, pleural effusion, etc in these groups. The incidence of all extranodal involvement in the high VEGF group and in the low VEGF group were 14/19 (73.7%) and 4/22 (18.1%), respectively. This difference was also statistically significant (P Ͻ 0.01, Fisher's method). Taken together, our observations suggest that VEGF at high plasma levels is closely associated with the extranodal involvement in ATL. The cell surface sialyl Lewis X, a ligand for selectin playing an important role in angiogenesis, was reported to be associated with ATL skin involvement.
3 Furthermore, HTLV-1 Tax protein was shown to induce the selection ligand on ATL cells, 4 indicating that angiogenesis is intimately involved in ATL skin invasion. Since VEGF is a potent stimulator of angiogenesis, it may play an important role in these patients, such as promoting, maintaining or stimulating the skin involvement. Moreover, VEGF has been found to inhibit the function of Langerhans cells, which play a crucial role in generation of antitumor immune responses in the skin.
5 According to this view, VEGF may allow ATL skin invasion to avoid an immune response. A complication of pleural effusion and ascites was also seen in only patients with high VEGF levels ( Table 1 ). Since VEGF is also known as a vascular permeability factor, it may act as an inducer of ATL growth in those third space fluids. In fact, VEGF has been demonstrated to be a major capillary permeability agent in ovarian hyperstimulation syndrome, characterized by enlargement of ovaries associated with third space fluid shift, resulting in the formation of ascites and pleural effusion. 6, 7 This is the first report to show the close correlation between a high VEGF level and extranodal involvement in ATL, and further studies are needed to clarify the origin of VEGF, as well as its exact role in the biology of ATL. 
TO THE EDITOR
We and others have reported that a small proportion of Ph+ CML patients lack the M-BCR rearrangement since they have break points that fall outside M-BCR.
1,2 Some of these patients may express e1a2 BCR-ABL transcript. In another subset of patients, we previously described a new variant of BCR-ABL transcripts named c3a2 (or e19a2), 3, 4 which gives rise to a p230 kDa BCR-ABL protein, in which the breakpoint was positioned 3Ј part on BCR gene.
Herein, a novel type of the chimeric BCR-ABL mRNA transcript was detected in a patient with Philadelphia chromosome positive (Ph+) chronic myeloid leukemia (CML) by reverse-transcription polymerase chain reaction (RT-PCR). Conditions for RT and PCR for BCR-ABL have been described 5, 6 (Figure 1a ). In the initial screening by PCR, no product of amplification was found with AZ (ABL exon a2) and EA12 (BCR exon e11) primers (for e13a2 or e14a2 junctions hand, an atypical amplification product was detected using primer R112 (BCR exon e1) and AZ (for e13a2 junction), which was considerably larger than expected: 1145 vs 331 base pairs (bp) 6 (Figure 1a ). BCR-ABL cDNA PCR products were directly sequenced and analyzed by FASTA3 analysis. 7 In both strands, the fragment investigated showed high homology between 5Ј part of exon 8 of the BCR gene (e8) and exon a2 of the ABL gene.
The homology with the exon 8 of BCR gene ended at nucleotide (nt) 107 807 of the reported BCR sequence.
2 Thirty-one bp of the fragment, positioned between the homologies of the BCR and ABL exons did not match either with BCR exon 8 or with the ABL sequences. Homology search demonstrated that this stretch of nucleotides matched with an intronic sequence of ABL intron Ib 2 spanning from nt 53 340 to 53 370. Homology of our BCR-ABL fragment with the second exon of the ABL gene was complete starting from nt 49 888 of the ABL2 clone, 2 corresponding to ABL exon 2. To our knowledge, no BCR break has hitherto been reported to fall in the BCR gene exon. In order to assess whether (1) the break on the BCR exon 8 fell inside the coding sequence and (2) the junction with ABL intron Ib sequences was due to a DNA link and not to a splice event, we performed the amplification on genomic DNA of the 5Ј BCR breakpoint region and a direct sequencing of the PCR product.
